Skip to main content

Drug-Drug Interaction Healthy Volunteers

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pharmbio Korea
Pharmbio KoreaKorea - Seoul
1 program
1
R1_PBK_M2301Phase 11 trial
Active Trials
NCT07017335Completed24Est. Aug 2025
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
1 program
Midazolam 5mg SyrupPHASE_11 trial
Active Trials
NCT02204501Completed24Est. Jun 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pharmbio KoreaR1_PBK_M2301
VaxartMidazolam 5mg Syrup

Clinical Trials (2)

Total enrollment: 48 patients across 2 trials

Drug-Drug Interaction Between R1_PBK_M2301 and R2_PBK_M2301 in Healthy Adults

Start: Jun 2025Est. completion: Aug 202524 patients
Phase 1Completed
NCT02204501VaxartMidazolam 5mg Syrup

A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers

Start: May 2014Est. completion: Jun 201424 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.